Starling Oncology, Inc.
STLN- Exchange
- Nasdaq
- Industry
- Services-Offices & Clinics of Doctors of Medicine
- SEC CIK
- 0001799191
In the last 90 days, Starling Oncology, Inc. insiders filed 3 open-market purchases and 2 sales; 119 institutions reported holding it in 13F filings for Q2 2026, worth $217.6M in total; no superinvestor holds it.
Holders of 5% or more of STLN
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Starling Oncology, Inc., largest stake first. The change is against the holder's previous filing.
No holder currently reports owning 5% or more of Starling Oncology, Inc. on Schedule 13D or 13G.
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
3 Schedule 13D and 13G filings on Starling Oncology, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Jun 24, 20257:40 PM ET | FOG Ventures Investments, LLCand 1 other | 13G/A | 0.00%0 shares | –Below 5% | May 15, 2025 | SEC |
| Apr 23, 20256:20 PM ET | Sarin Ravi Yangand 1 other | 13D/A | 4.70%4.11M shares | –Below 5% | Mar 26, 2025 | SEC |
| Dec 6, 202411:50 AM ET | FMR LLCand 1 other | 13G/A | 0.00%0 shares | –Below 5% | Nov 29, 2024 | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Starling Oncology, Inc. shares.
No Form 144 notices for Starling Oncology, Inc. are on file.